Funding round
eGenesis Series A
eGenesis, which works in xenotransplantation solutions development in Cambridge, raised $38M in a Series A round announced on 16 Mar 2017, led by Biomatics Capital and ARCH Venture Partners. 10 firms took part. It is eGenesis' first venture round on record.
$38M
Amount raised
Not disclosed
Post-money valuation
10
Investors
2 leads
Valuation
What this round says about the price
eGenesis did not disclose a valuation in this round. It is eGenesis' first venture round on record, 2 years after it was founded in 2015. It is 8.4% of the $454M eGenesis has raised in the venture rounds on record. eGenesis raised again 32 months later: a Series B round of $100M in Nov 2019.
eGenesis' funding rounds
eGenesis has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Biomatics Capital and ARCH Venture Partners led the round with 8 other firms.
Lead investors
- Biomatics Capital new investor
- ARCH Venture Partners backs 99 venture-backed companies new investor
Also in the round
- Khosla Ventures backs 396 venture-backed companies new investor
- backs 18 venture-backed companies new investor
- Alexandria Venture Investments new investor
- Heritage Provider Network new investor
- backs 7 venture-backed companies new investor
- Uprising new investor
- Fan Ventures new investor
- backs 15 venture-backed companies new investor
Joined the board: Daniel S. Lynch.
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
35 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $12M, and this round was 3.2 times the median. The closest in time, other companies' Series A rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 17 Mar 2017 | $3.2M | not disclosed | not named |
| Biotechnology | 2 Feb 2017 | $9.0M | not disclosed | GreyBird Ventures |
| Biotechnology | 24 Feb 2017 | $3.5M | not disclosed | not named |
| Biotechnology | 4 May 2017 | $41M | not disclosed | Novartis Venture Fund and Columbus Venture Partners |
| Biotechnology | 2 May 2017 | $22M | not disclosed | Boehringer Ingelheim Venture Fund and Kurma Partners |
| Biotechnology | 24 Jan 2017 | $20M | not disclosed | Qiming Venture Partners |
| Biotechnology | 19 May 2017 | $16M | not disclosed | ARCH Venture Partners |
| Biotechnology | 5 Jan 2017 | $9.5M | not disclosed | Boehringer Ingelheim Venture Fund GmbH and Novo Holdings |
Sources
Where this comes from
Reported by 2 sources.
Questions
Frequently asked
How much did eGenesis raise in its Series A round?
eGenesis raised $38M in its Series A round, announced in Mar 2017.
Who led eGenesis' Series A round?
Biomatics Capital and ARCH Venture Partners led it, with Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network and Berggruen Holdings and 3 more.
What was eGenesis' valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Biotechnology?
35 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $12M, and this round was 3.2 times the median.
Did eGenesis raise again after this round?
Yes: a Series B round in Nov 2019 of $100M.